Ipiilimumab and Nivolumab/Pembrolizumab in Advanced Hepatocellular Carcinoma Refractory to Prior Immune Checkpoint Inhibitors

Advanced HCC patients who progressed on prior immune checkpoint inhibitors

In Brief
Ipiilimumab and nivolumab/pembrolizumab demonstrated a 16% objective response rate, 12% complete response rate and median overall survival of 10.9 months in advanced HCC patients with progression on prior immune checkpoint inhibitors.

Authors
Jeffrey Sum Lung Wong, Gerry Gin Wai Kwek, Vikki Tang, Bryan Cho Wing Li, Roland Leung, Joanne Chiu, Ka Wing Ma, Wong Hoi She, Josephine Tsang, Chung Mau Lo, Tan To Cheung, Thomas Yau

Correspondence
jywcc@hku.hk

Response rate similar regardless of prior immune checkpoint inhibitor response
All responders were Child-Pugh A
Child-Pugh and Albumin-Bilirubin grades significantly associated with OS